Latest News and Press Releases

Wichtiger Meilenstein zur Vorbereitung des europäischen Markteintritts und Beleg des Engagements für Qualität Los Angeles, USA - 9. April 2025 - ANEUVO, ein Pionier auf dem Gebiet der Entwicklung...

First-ever use of Ebenbuild’s Twinhale technology  in idiopathic pulmonary fibrosis lung modelsTrial results published in Nature Communications Munich, Germany – April 9, 2025 -- Ebenbuild, a company...

Presentation by Prof. Anand Deva highlights 87% breast volume retention and low complication rate in one-year patient follow-upSuccessful vascularization and vessel formation in two-year follow-up...

Findings highlight underexplored role of intestinal brush border in protein digestion, and its vulnerability to inflammatory damage in celiac disease Review discusses potential benefits of...

One-year follow-up data confirm favorable safety profile of BellaSeno´s scaffolds compared to silicone implantsCompany plans expansion to primary breast augmentation and lumpectomy Leipzig, Germany/...

- tiakis and Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH) Kiel, Germany, January 8, 2025 – tiakis Biotech AG, a clinical-stage biopharmaceutical company...

Novel paradigm for therapeutics based on RNA splicing modulationLead program in Huntington’s disease Denmark – Odense – 07/01/2025 – Inverna Therapeutics, a novel Danish biotech company at the...

-       Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing...

Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3 Munich, Germany – December 4, 2024 – Thermosome, a drug development company...

THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activityData presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 Munich,...